Klein R, Classen K, Berg P A, Lüdtke R, Werner M, Huber R
Department of Internal Medicine II, University of Tübingen, Germany.
Eur J Med Res. 2002 Apr 30;7(4):155-63.
Several studies have been performed in tumour patients to analyse the immunological response to mistletoe extracts. Considering the fact that these extracts are given subcutaneously in most instances, the kind of application resembles a typical immunization schedule. We therefore wanted to see how those extracts act on immunocompetent cells of healthy individuals hoping that this kind of provocation test may give new informations about a more specific application of these extracts in certain diseases.
SUBJECTS/METHODS: 47 healthy individuals were exposed for twelve weeks either to Iscador Quercus special (IQ) known to be rich in mistletoe lectin (ML)-1 (n = 16), to Iscador Pini (IP) being poor in ML-1 but enriched in viscotoxins (n = 15), or to placebo (physiological saline) (n = 16) in a randomised, double-blinded placebo-controlled study. Humoral immunoreactivity was analysed by measuring antibodies towards the two compounds ML-1 and viscotoxin VA2 (VA2). Sera were collected in intervals of four weeks up to week 12 and again three months after last exposure.
None of the subjects had antibodies to ML-1 or VA2 before exposure. In week 12, anti-ML-1 antibodies of the IgG-type were found in all 16 IQ-treated individuals but only 6 of the 15 probands exposed to IP. In contrast, anti-VA2 IgG-antibodies could be detected in all individuals of both groups. The antibodies were preferentially of the IgG1 and IgG3 type while antibodies of the IgA and IgM type were produced only in a few probands. Antibodies of the IgE-type occurred only in the IQ-exposed individuals and were directed against ML-1 but not VA2. None of the probands receiving placebo developed antibodies to ML-1 or VA2. Severe side effects were not observed in any of the probands.
These data obtained in healthy individuals clearly indicate that IQ and IP-extracts can induce antigen-specific humoral responses. They may, therefore, provide, a solid basic for the evaluation of the humoral immune response in disease states.
已对肿瘤患者进行了多项研究,以分析其对槲寄生提取物的免疫反应。鉴于这些提取物在大多数情况下是皮下注射给药,其应用方式类似于典型的免疫接种方案。因此,我们想了解这些提取物对健康个体的免疫活性细胞有何作用,希望这种激发试验能为这些提取物在某些疾病中的更具体应用提供新信息。
受试者/方法:在一项随机、双盲、安慰剂对照研究中,47名健康个体被暴露于富含槲寄生凝集素(ML)-1的Iscador Quercus special(IQ)(n = 16)、ML-1含量低但富含毒肽的Iscador Pini(IP)(n = 15)或安慰剂(生理盐水)(n = 16)中,为期12周。通过测量针对两种化合物ML-1和毒肽VA2(VA2)的抗体来分析体液免疫反应性。每隔四周采集血清,直至第12周,并在最后一次暴露后三个月再次采集。
暴露前,所有受试者均无针对ML-1或VA2的抗体。在第12周时,在所有16名接受IQ治疗的个体中均发现了IgG型抗ML-1抗体,但在15名接受IP治疗的受试者中仅6人发现。相比之下,两组所有个体均可检测到抗VA2 IgG抗体。这些抗体主要为IgG1和IgG3型,而IgA和IgM型抗体仅在少数受试者中产生。IgE型抗体仅在接受IQ治疗的个体中出现,且针对ML-1而非VA2。接受安慰剂的受试者均未产生针对ML-1或VA2的抗体。所有受试者均未观察到严重副作用。
在健康个体中获得的这些数据清楚地表明,IQ和IP提取物可诱导抗原特异性体液反应。因此,它们可为评估疾病状态下的体液免疫反应提供坚实基础。